Global Red Biotechnology Market Size study & Forecast, by Product (Monoclonal Antibodies, Polyclonal Antibodies, Vaccines, Cell-Based Immunotherapy Products, Gene Therapy Products, Others), by End-user (Academic Research Institutes, CMOs & CROs, Pharmaceu

Global Red Biotechnology Market Size study & Forecast, by Product (Monoclonal Antibodies, Polyclonal Antibodies, Vaccines, Cell-Based Immunotherapy Products, Gene Therapy Products, Others), by End-user (Academic Research Institutes, CMOs & CROs, Pharmaceutical & Biotechnology Companies, Others) and Regional Analysis, 2023-2030

Global Red Biotechnology Market is valued at approximately USD 515.58 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 10.6% over the forecast period 2023-2030., Red biotechnology, also known as medical biotechnology, refers to the branch of biotechnology that focuses on using living organisms or their products to develop new medical and pharmaceutical products and applications. This field is called ""red"" biotechnology because it primarily deals with healthcare-related applications, and the color red is often associated with the medical and pharmaceutical industries. The key factors driving the market growth is Increasing Healthcare Expenditure, growing old age population, Rising Prevalence of Chronic Diseases, and growing development and production of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and vaccines that anticipated to support the market growth during projected period.

According to The World Bank, in 2020, it was expected that aging people around the world accounted for 1 billion, which is projected to reach 1.5 billion by the year 2030 which represents that 1 in 6 people are more than 60 years of age. As a result, the growing old age population is anticipated to support the market growth. Additionally, growing research and development activities is anticipated to create the lucrative opportunity for the market during forecast period.
However, the costly therapeutic technology and machinery stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Red Biotechnology Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of key market players, rising healthcare expenditure, and growing research and development activities. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the growing old age population, rising demand for the personalized medicine, and growing Clinical Trials and Research that anticipated to support the region growth.

Major market player included in this report are:
F. Hoffmann-La Roche AG
Pfizer Inc
Regeneron Pharmaceuticals, Inc
Gilead Sciences Inc.
Biogen Inc.
Amgen Inc.
Celgene Corporation
Takeda Pharmaceutical Company Limited
AstraZeneca Plc
Merck KGaA

Recent Developments in the Market:
 In August 2022, The U.S. FDA approved MYFEMBREE, a once-daily medication produced by Myovant Sciences and Pfizer with a 24-month maximum treatment period, for the management of moderate to severe endometriosis-related pain. For the management of mild to severe endometriosis-related pain, MYFEMBREE offers an effective once-daily therapeutic alternative.
Global Red Biotechnology Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Product, End-User, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Monoclonal Antibodies
Polyclonal Antibodies
Recombinant Proteins
Vaccines
Cell-Based Immunotherapy Products
Gene Therapy Products
Cell Therapy Products
Tissue-Engineered Products
Stem Cells
Cell Culture
Viral Vector
Enzymes
Kits and Reagents
Animal models
Molecular diagnostics
Others

By End-User:
Academic Research Institutes
CMOs & CROs
Pharmaceutical & Biotechnology Companies
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
F. Hoffmann-La Roche AG
Pfizer Inc
Regeneron Pharmaceuticals, Inc
Gilead Sciences Inc.
Biogen Inc.
Amgen Inc.
Celgene Corporation
Takeda Pharmaceutical Company Limited
AstraZeneca Plc
Merck KGaA

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.